home

LATEST ONCOPRESCRIBE UPDATES

• Capivasertib Plus Fulvestrant Improves Progression Free Survival in Advanced Hormone Receptor Positive Breast Cancer

• BRUKINSA® Superior to IMBRUVICA® in Relapsed/Refractory CLL/SLL

• NALIRIFOX Improves Overall Survival in Patients with Metastatic Pancreatic Cancer

• Biomarkers May Predict Response to Enfortumab Vedotin in Advanced Urothelial Cancer

• FDA Expands Adjuvant VERZENIO® Indication in High-Risk Early Breast Cancer

• Five Year Outcomes with KEYTRUDA® Plus Chemotherapy in Metastatic Nonsquamous Non Small Cell Lung Cancer

• Overall Survival Benefit with Pembrolizumab in Advanced Gastric Cancer

• Rucaparib or Physicians Choice of Therapy in Metastatic Prostate Cancer

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Molecular Tidbits

NEW REGIMENS ADDED

Research Regimens

• TIBSOVO® - for Acute Myeloid Leukemia

• Single Agent LUMAKRAS® - for Non Small Cell Lung Cancer

• KEYTRUDA® - for Malignant Melanoma

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• KEYTRUDA® plus INLYTA® - for Renal Cancer

Curbside Consultation

Lung Cancer Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• TTP, HUS and aHUS: Different diseases – Different treatments

• HER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE